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Changes in T cell effector functions 
over an 8-year period with TNF 
antagonists in patients with chronic 
inflammatory rheumatic diseases
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The aim of the study was to clarify the effect of long-term anti-TNF therapy on T cell function in 
patients with rheumatologic immune-mediated inflammatory diseases (IMID). The production of 
IFNγ by T cells was evaluated at baseline and after 1, 2, 4, and 8 years of anti-TNF agents by means 
of a QuantiFERON-TB Gold In-Tube assay. The T cell proliferation and surface co-expression of CD25/
CD134 in response to phytohaemagglutinin together with the in vitro impact of anti-TNF therapy 
on the functional capacity of T cells were evaluated after 8 years from the onset of the biological 
treatment. Age-matched healthy donors were enrolled as controls. The quantitative mitogen-induced 
IFNγ responses significantly increased with respect to baseline at each time point, apart from the 
determination after 4 years. We found an increased expression of CD25/CD134 in CD4+ compared to 
CD8+ T cells both in patients and controls. The in vitro addition of anti-TNF agents induced a significant 
decrease of both the IFNγ response and of CD25/CD134, whereas no effect on the intensity of the 
proliferative response was observed. Our data provide a biological basis for the reassuring issues on the 
safety of long-term anti-TNF treatment in patients with IMID.
Tumor necrosis factor (TNF) drives the early cytokine cascade at sites of inflammation1. TNF-targeted biological 
therapy with monoclonal antibodies (infliximab, adalimumab, golimumab, certolizumab pegol) or soluble recep-
tors (etanercept) dramatically changed the course of several chronic inflammatory diseases such as rheumatoid 
arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis, psoriasis (PsO), and inflammatory bowel disease 
(IBD)2. Most of the favorable outcomes of these agents have been attributed to their ability to antagonize the 
effects of TNF at late steps of the inflammatory cascade3.
TNF antagonists have been assessed for immune system effects, including ex vivo assays of cells from treated 
patients. Previous studies reported that these drugs suppress cytokine production by circulating effector T cells4–11, 
although an enhanced synthesis of TNF and interferon γ (IFNγ) by T cells upon in vitro stimulation has also been 
reported12. Likewise, Bosè et al. evidenced a dual effect in patients with PsO and IBD, in which TNF blockade 
was capable of inducing an augmented responsiveness of peripheral T cells to TCR-stimulation and an increased 
secretion of cytokines ex vivo, whereas in biopsies from target tissues TNF blockade led to a dramatic reduction 
of Th17 and Th1 responses13.
IFNγ release assays (IGRAs) provide the most recent method to diagnose latent tuberculosis (LTBI) infec-
tion and are increasingly used as a screening tool in patients undergoing treatment with anti-TNF agents14. 
IGRAs measure the cell-mediated immune response against some M. tuberculosis specific antigens and incor-
porate an internal positive control (phytohaemagglutinin, PHA), which tests the ability of T cells to produce 
IFNγ15. A recent meta-analysis showed that glucocorticoids, oral immunosuppressants and biological therapy 
produce more negative, but not indeterminate, IGRA results16. However, only five studies on anti-TNF agents 
were included in this meta-analysis17–21 and, among these, only two were performed in patients with autoimmune 
diseases, in which a clinical evaluation was done without a determination of the biological effects of anti-TNF 
agents on IGRA outcome18,19.
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Therefore, we decided to clarify the ex vivo effect of long-term anti-TNF therapy on T cell effector function in 
subjects with rheumatologic immune-mediated inflammatory diseases (IMID). To this purpose, we performed 
multiple investigations comprising IFNγ secretion by means of an IGRA assay, and T cell proliferation and sur-
face co-expression of CD25 and CD134 in response to PHA. Furthermore, we examined the in vitro impact of 
anti-TNF biological therapy with etanercept (Eta) or adalimumab (Ada) on the functional capacity of T cells.
Methods
Study population. Starting from 2008, we conducted a longitudinal, prospective, observational study on 
patients with IMID referring to the rheumatology outpatient clinic at Sapienza University of Rome, Italy, and 
candidates to an anti-TNF agent as their first biological treatment. Before starting anti-TNF agents, patients 
underwent screening for LTBI, including a postero-anterior chest radiograph and the QuantiFERON-TB Gold 
In-Tube (QFT-GIT) assay (Cellestis GmbH, QIAGEN Inc. Valencia, CA, USA), one of the currently available 
IGRAs. The original population consisted of 102 patients who were initially studied to assess possible QFT-GIT 
conversions and reversions in relation to the clinical outcome during the initial 18 months of treatment with bio-
logical therapy22. Thirty-three of these patients were also involved in another study with the aim to analyse CD4+ 
T cells by multi-functional flow cytometry during a total of 36-month follow-up of their treatment with biological 
therapy23. Among patients of this last group, only those continuing biological treatment for at least 8 years were 
included in the current study. At established time points, taken before (T0) and after 1 (T1), 2 (T2), 4 (T4), and 8 
(T8) years since the onset of anti-TNF agents, blood samples were collected from IMID subjects to measure the 
IFNγ secretion. Blood samples obtained after 8 years of biological therapy were used to perform the proliferation 
assay, together with the co-expression of CD25/CD134 assay. These two tests, as well as the IFNγ secretion, were 
also performed in a group of healthy donors (HD). At the same time as the blood draws, in patients with IMID 
disease activity was calculated by using a validated index, the modified disease activity score (DAS28)24.
The study received approval from the Policlinico Umberto I Ethics Committee (reference number 2669). The 
study was conducted in accordance with approved guidelines and regulations, and all of the participants provided 
written informed consent.
Ex vivo assays. QuantiFERON TB Gold-In Tube assay. Whole blood from IMID subjects was tested using 
the QFT-GIT assay (Cellestis GmbH, QIAGEN Inc. Valencia, CA, USA) according to the manufacturer’s instruc-
tions. The result was considered indeterminate if IFN γ level of mitogen minus that of the negative control was 
<0.5 IU/mL and/or if IFNγ level of the negative control was >8.0 IU/mL. Analysis of data was done with the 
QFT-GIT analysis software.
CD25/CD134 assay and flow cytometry procedures. Heparinized peripheral blood (0.5 ml) was mixed with an 
equal volume of RPMI-1640 Medium (Sigma-Aldrich, Germany), and then incubated in sterile 24-well culture 
plates with PHA (5 μg/mL, Sigma-Aldrich, Germany) or medium alone at 37 °C in 5% CO2 for 44–48 hours before 
antibody staining and analysis by flow cytometry.
After 44 hours of incubation, 100 μl of whole blood was stained with anti-CD3 PerCP, anti-CD4 PE-Vio770, 
anti-CD25 APC, anti-CD8 FITC (BD Biosciences, San Josè, USA), anti-CD134 PE (BioLegend, San Diego, CA, 
USA) for 20 min at 4 °C, followed by treatment with FACS lysing solution (BD Biosciences, according to manufac-
turer’s instructions) and washed twice with FACS buffer (PBS/0.5% BSA, 0.01% sodium azide). Cells were fixed in 
1% paraformaldehyde and acquired within 1 hour using a MACSQuant Analyzer flow cytometer (MiltenyiBiotec, 
Germany) after calibration and automatic compensation. From each sample, a minimum of 100.000 events was 
collected and analyzed using FlowJo software v. 10 (Tree Star, San Carlos, CA, USA). Lymphocytes were identified 
on the basis of forward and side-scatter; after gating on CD3+CD4+ T cells and CD3+CD8+ T cells, an analysis of 
CD25 APC and CD134 PE staining events was performed. Standard gating procedures using fluorescence minus 
one (FMO) controls (unstimulated) were used to identify positive cells. Background CD25+/CD134+ expression 
in negative control was subtracted from stimulated condition. The cut-off for a positive response was calculated 
as the mean response (%) + 3 standard deviation (SD) above negative control from HD.
T cell proliferation assay and flow cytometry procedures with data analysis. Peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood of patients with IMID and HD by density-gradient centrifugation on 
Ficoll-Histopaque (Sigma-Aldrich, Germany). Fresh PBMCs, at a density of 1 × 106 cells/mL, were labelled with 
5 μM CellTrace Violet (CTV) fluorescent dye (Molecular Probes, Invitrogen, CA, USA) with immediate vortexing 
to ensure rapid and homogeneous labelling of cells. Cells were then incubated at 37 °C for 20 min and washed 3 
times with RPMI-1640 Medium (Sigma-Aldrich, Germany) supplemented with 10% heat-inactivated fetal calf 
serum (FCS, Gibco, CA, USA). Fluorescent dye-labelled PBMCs were cultured at a concentration of 1.5 × 106 
cells/mL in RPMI-1640 Medium, supplemented with 2 mM L-glutamine, 1% of penicillin/streptomycin, 10% 
FCS, in the presence of PHA (5 μg/mL, Sigma-Aldrich, Germany) or medium alone at 37 °C in 5% CO2 for 5 days.
On day 5 of culture, the cells were stained with anti-CD3 PerCP, anti-CD4 PE-Vio770, anti-CD8 PE 
(MiltenyiBiotec, Germany) for 20 min at 4 °C, and fixed with 1% paraformaldehyde.
Samples were acquired within 1 hr using MACSQuant Analyzer Flow Cytometry (MiltenyiBiotec, Germany), 
after calibration and automatic compensation, and analyzed with Flow Jo software v. 10 (Tree Star, San Carlos, 
CA, USA). The proliferation fraction (PF) of gated CD4+ and CD8+ T cells was quantified based on CTV dilution 
and shown as percentage of CD4+ and CD8+ T cells in CTVlow gate. The gating strategy used to identify T cell 
proliferation is shown in Supplementary Fig. S1. The ΔPF was calculated subtracting the negative control PF 
from the PHA-induced PF. As negative controls, we used labelled unstimulated cells which provide a fluorescence 
measurement of non-proliferating lymphocytes. To normalize the values, we calculated the stimulation index 
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(SI), which represents the proportion of cells proliferating in response to PHA divided by the proportion of cells 
proliferating spontaneously in medium. SI values > 2 were considered as positive proliferative response25.
In vitro assay. For in vitro experiments, whole blood and fresh fluorescent dye-labelled PBMCs of 3 HD 
were cultured, as described above, in the presence of PHA (5 μg/mL). TNF blockers were added at trough and 
peak drug concentrations, and also at supratherapeutic concentration (Eta at 1, 2, and 5 μg/mL; Ada at 5, 10, and 
15 μg/mL) reached in blood during therapy, on the basis of information provided by manufacturers26,27. Positive 
control wells contained PHA only, and negative control wells contained medium alone. All conditions were set 
up in triplicate wells.
After 18–24 hours of culture at 37 °C in 5% CO2, the supernatants were collected and IFNγ levels were meas-
ured according to the manufacturer’s instructions (Cellestis GmbH, QIAGEN Inc. Valencia, CA, USA). All data 
were background-corrected by subtracting measured IFNγ concentration of the negative sample from those of the 
PHA-stimulated sample. After 44 hours of incubation at 37 °C in 5% CO2, the frequency of CD25+CD134+ T cells 
was assessed as described above, in the presence or absence of the biological drug. After 5 days of culture at 37 °C 
in 5% CO2, T cell proliferation was assessed, as described above, in the presence or absence of the biological drug.
Statistical analysis. Median (interquartile range, IQR) or mean (±SD) of the different parameters 
were calculated. Longitudinal analysis was evaluated with the non-parametric Wilcoxon-signed-rank test. 
Non-parametric Mann-Whitney test was used to compare the continuous demographic characteristics of IMID 
patients and HD and the T cell responses between two groups. Pearson correlation coefficient was used to exam-
ine the correlation between IFNγ secretion assay and parameters from flow cytometric analysis (T cell prolifer-
ation and co-expression of CD25+/CD134+). Student’s t test was used for statistical analysis of data from in vitro 
experiments with TNF antagonists. All statistical analyses were two-sided, performed using GraphPad Prism 
Software v. 5 (Software MacKiev), and considered significant at p-values < 0.05.
Data Availability. The datasets generated and/or analysed during the current study are available from the 
corresponding author on reasonable request.
Results
Study subjects. The main characteristics of the patients included in the study and their therapeutic profile 
are summarized in Table 1. Of the 33 patients participating in the multi-functional flow cytometry study23, only 
15 had a complete 8-year follow-up and were considered for the present study. The reasons for discontinuation 
were the following: withdrawal of biological treatment due to inefficacy or adverse events (n = 15), refusal to allow 
a blood draw (n = 2), lost-to-follow-up (n = 1). Of the enrolled patients, 7 had a diagnosis of RA and 8 of PsA 
according to standard criteria28,29. Ten patients (66%) initiated treatment with Eta and 5 (33%) with Ada. Eleven 
age-matched HD were enrolled as controls (Table 1).
Ex vivo assays. Impact of biological agents on the mitogen-induced IFNγ response. In order to study the 
effect of long-term TNF antagonist treatment on T cell response, we first analyzed the ability of IMID subjects to 
secrete IFNγ by comparing both the rate of indeterminate QFT-GIT results and the quantitative mitogen-induced 
IFNγ responses, corresponding to the maximum IFNγ response, at different time points, i.e. before and after 1, 2, 
4 and 8 years of biological therapy.
The prevalence of indeterminate QFT-GIT results did not significantly change in the cohort of patients over 
the long-term follow-up (p > 0.05), indicating that the performance of this assay was not affected by the biological 
therapies (Table 2).
Conversely, significant changes occurred in the quantitative mitogen-induced IFNγ responses following treat-
ment with TNF antagonists. In particular, as shown in Fig. 1a, the IFNγ response in IMID patients increased 
significantly at T1 (p = 0.03) and T2 (p = 0.003) with respect to baseline, decreased significantly at T4 with respect 
IMID HD
(n = 15) (n = 11)
M/F (n) 7/8 6/5
Age (years; median/IQR) 60/52-68 51/41-65*
Underlying disease (n)
  Rheumatoid arthritis 7 —
  Psoriatic arthritis 8 —
Concomitant treatment regimen (n/%)
  Biologics 6/40 —
  Biologics + glucocorticoids 4/27 —
  Biologics + DMARDs 4/27 —
  Biologics + DMARDs + glucocorticoids 1/6 —
Table 1. Demographics and clinical characteristics of the patients after eight years of anti-TNF biological 
treatment. *Statistical analysis was performed using the Mann-Whitney test (p = 0.15). Note: IMID = immune-
mediated inflammatory diseases; HD = healthy donors; IQR = interquartile range; DMARDs = disease 
modifying anti-rheumatic drugs (include methotrexate and leflunomide).
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to T2 (p = 0.002), and showed a further significant increase at T8 with respect to T4 (p = 0.0015) and to base-
line (p = 0.03). The levels of IFNγ at T4 were similar to those observed at baseline. The mitogen-induced IFNγ 
response increased 0.77 and 1.49-fold at T1 and T2, respectively; significantly decreased by 60% (0.6-fold, from 
15.77 to 6.34 IU/mL) at T4 and increased 1.25-fold at T8.
The DAS28 values decreased significantly, with respect to baseline (median 4.76, IQR 4.5–5.1), at T1 (median 
2.79, IQR 1.7–3.4), T2 (median 2.27, IQR 1.6–3.2), T4 (median 2.31, IQR 1.9–2.9), and T8 (median 2.4, IQR 
1.7–2.8) (p < 0.0001 for all comparisons) (Fig. 1b).
Next, the quantitative mitogen-induced IFNγ response was evaluated according to the type of biological 
agent or the inflammatory disease. The IFNγ response showed a similar trend irrespective of the treatment 
(Eta or Ada) and the disease (RA or PsA) (Fig. 1c,d) during the 8-year course of follow-up. In particular, we 
observed a decrease of mitogen-induced IFNγ response after 4 years of therapy, mainly in patients treated with 
Eta (p = 0.019) and in those with RA (p = 0.046) with respect to time point T2.
The IFNγ response was also analyzed by comparing all IMID subjects after 8 years of treatment with TNF 
antagonists and HD. The responses induced by PHA in patients (median 14.2 IU/mL, IQR 13–16.9) were in 
the same range as those of HD (median 13 IU/mL, IQR 10–19.3; p = 0.95) (Fig. 1e). Serial numerical changes 
occurred in the mitogen-induced IFNγ responses from QFT-GIT of IMID patients at the different time points 
during treatment with TNF antagonists are summarized in Table 2.
Impact of biological agents on the CD25/CD134 assay. Co-expression of CD25 and CD134 by T cells in 
PHA-stimulated whole blood cultures of 44 hours duration was assessed in IMID patients after 8 years of bio-
logical therapy. Background co-expression of CD25 and CD134 on T cells was extremely low, as shown in a 
representative un-stimulated 44 hour-whole blood culture (Fig. 2a). Un-stimulated cultures from HD were used 
to determine the cut-off for a positive response, designed as the mean response (%) + 3 SD of the negative control.
Flow cytometric analysis in IMID patients showed frequencies of PHA-stimulated CD25+CD134+CD4+ T 
cells (median 20.4%, IQR 7.7–27.8%) higher than CD25+CD134+CD8+ T cells (median 9.82%, IQR 3.5–14.8%; 
p = 0.0181) (Fig. 2b). Indeed, based on positive cut-off, corresponding to 0.47% (mean 0.09, SD 0.12) for CD4+ T 
cells, and 0.41% (mean 0.11, SD 0.09) for CD8+ T cells, we scored as positive all 15 IMID patients assessing both 
the CD4+ and CD8+ T cells.
We also compared the co-expression of surface markers between patients treated with Eta and Ada. Again, 
the co-expression of CD25 and CD134 was mostly present on CD4+ than CD8+ T cells with either treatments 
(p < 0.05 for all comparisons). However, patients treated with Ada showed a trend towards more activated T cells 
(median 26.5%, IQR 14.4–33.6% for CD4+ and median 12.5%, IQR 6.9–18.3% for CD8+) as compared to those 
treated with Eta (median 14.6%, IQR 7–27.2% for CD4+ and median 4.8%, IQR 2.5–13.9% for CD8+) (p = 0.16 
for CD4+ and p = 0.25 for CD8+; Fig. 2c).
Among HD, a high percentage of PHA-stimulated CD25+CD134+ in both T cell subsets was observed, with 
frequencies of CD4+ T cells (median 37.8%, IQR 31.6–46.5%) greater than those of CD8+ T cells (median 19.7%, 
IQR 12.1–38.1%; p = 0.01). Finally, the frequency of CD4+ and CD8+ T cells positive for CD25 and CD134 was 
significantly higher in HD as compared to IMID subjects (p = 0.0004 for CD4+ and p = 0.0059 for CD8+) (Fig. 2b).
No correlation was found between DAS28 and the frequency of CD25+CD134+CD4+ T cells (r = −0.19, 
p = 0.49, r2 = 0.03) or CD25+CD134+CD8+ T cells (r = 0.005, p = 0.98, r2 = 0) (data not shown).
Impact of biological agents on the T cell proliferation assay. The proliferative capacity of CD4+ and CD8+ T cells 
from IMID patients was measured after 8 years of biological treatment and data were compared to those obtained 
from HD. After inducing proliferation, T cells were identified by flow cytometry as a result of fluorescence dim-
inution from CTV labelling. Figure 3a shows CTV-fluorescence obtained stimulating PBMCs with PHA for 5 
days. Cells proliferating in response to PHA were clearly detectable, as their CTV-fluorescence intensity was 
lower than the major population in the parental generation, and was expressed as percentage of CD4+CTVlow and 
CD8+CTVlow T cells. Gating CD3+CD4+ and CD3+CD8+ T cells separately, we observed a positive proliferative 
response (SI > 2) to PHA, with frequencies ranging from 37.9% to 79.5% for CD4+ T cells, and from 20% to 72.4% 
for CD8+ T cells in IMID individuals. The comparison of proliferative responses between CD4+ and CD8+ T cells 
among treated subjects did not reveal any significant differences (median 58.7% vs 50.43%, p = 0.17) (Fig. 3b).
QFT-GIT (IU/mL) results during biological treatment
Baseline* 1 year 2 years 4 years 8 years
All patients (n = 15) 6.3 (2.7–16.9) 11.2 (8.09–14.6) 15.7 (10–30.4) 6.3 (0.98–15.8) 14.2 (13–16.9)
Indeterminate results (n) 0 0 1 2 0
Etanercept (n = 10) 7.4 (2.7–19.3) 11.03 (4.8–24.5) 15.1 (9.6–30.5) 2.07 (0.7–12.9) 13.8 (11.7–16.9)
Adalimumab (n = 5) 5.06 (2.6–8.9) 11.8 (8.6–14.3) 20.5 (8.5–31.3) 8.4 (5.2–16) 14.3 (9.9–18.5)
RA (n = 7) 6.3 (2.7–16.9) 11.2 (2.6–12.7) 12.2 (8.7–15.7) 1.4 (0.4–6.9) 14.2 (13–17.7)
PsA (n = 8) 5.7 (2.8–16.8) 11.5 (9.1–15.9) 29.5 (12.6–31) 13.9 (4.7–15.9) 14.02 (7.8–16.8)
Table 2. Changes occurred in the quantitative mitogen-induced IFNγ responses from QFT-GIT taken at the 
different time points during treatment with TNF antagonists. *Prior to the onset of biological treatment. The 
values expressed as IU/ml are median with interquartile range. Note: QFT-GIT = QuantiFERON-TB Gold In-
Tube; RA = rheumatoid arthritis; PsA = psoriatic arthritis.
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When comparing patients treated with Eta and Ada, a constantly high proliferative capacity in both T cell 
subsets was observed. Interestingly, CD4+ and CD8+ T cells in Ada subjects were characterized by greater prolif-
erative responses (median 68.6% for CD4+, 65.04% for CD8+) than those observed in patients treated with Eta 
(median 55.3% for CD4+, 40.5% for CD8+), even if the difference was not statistically significant (p = 0.59 for 
CD4+ and p = 0.09 for CD8+) (Fig. 3c).
Next, we assessed the proliferative capacity of T cells among HD. The proliferative frequencies were similar, 
ranging from 47% to 93% for CD4+ T cells, and from 46.8% to 93.1% for CD8+ T cells. No significant differences 
were observed between CD4+ and CD8+ T cells (median 57.8% vs 59.8%, p = 0.94) (Fig. 3b). The comparison of 
Figure 1. Mitogen-induced IFNγ response from patients undergoing treatment with TNF antagonists. The 
release of IFNγ in response to phytohemagglutinin (PHA) was evaluated after 18 hours of incubation using 
the QuantiFERON TB Gold-In Tube (QFT-GIT; Cellestis GmbH, QIAGEN Inc. Valencia, CA, USA) assay, 
according to the manufacturer’s instructions. The figure shows the mitogen-induced IFNγ response during 
follow-up. (a) IFNγ response (IU/mL) after mitogen stimulation was assessed in 15 IMID subjects before 
and after 1, 2, 4, and 8 years of biological agents. (b) Changes in the DAS28 score in the IMID subjects at the 
different time points of the follow-up period. (c) The analysis of mitogen-induced IFNγ response was assessed 
according to the type of biological agent in patients treated with Eta (n = 10, black circle) and in those treated 
with Ada (n = 5, white circle). (d) The analysis of mitogen-induced IFNγ response was assessed according to 
the type of inflammatory disease in 7 patients with rheumatoid arthritis (RA, black circle) and in 8 patients with 
psoriatic arthritis (PsA, white circle). (e) The IFNγ response was assessed by comparing IMID subjects (n = 15) 
after 8 years of treatment with TNF antagonists and healthy donors (HD, n = 11). Horizontal bars represent 
the median values. Statistical analysis was calculated by Wilcoxon Rank test for longitudinal data and by non-
parametric Mann-Whitney test to compare IMID and HD subjects. Significant p-values are indicated.
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proliferative CD4+ and CD8+ T-cell responses between IMID and HD did not reveal any significant differences 
(median 58.7% vs 57.8% p = 0.71 for CD4+; median 50.43% vs 59.8%, p = 0.23 for CD8+) (Fig. 3b).
Correlations among IFNγ secretion, expression of CD25/CD134, and T cell proliferation. We examined possi-
ble correlations among cytokine production, activation and proliferation of T cells in IMID patients (Fig. 4). 
IFNγ response was positively correlated with the frequency of CD25+CD134+CD4+ T cells (r = 0.58, p = 0.021, 
r2 = 0.34) (Fig. 4a), but not with the proliferating CD4+ T cells in response to PHA (r = −0.18, p = 0.5, r2 = 0.034) 
(Fig. 4b). In addition, no correlation was found between the frequencies of CD25+CD134+CD4+ T cells and 
CD4+ T cell proliferation (r = 0.15, p = 0.5, r2 = 0.023) (Fig. 4c). The correlations for CD8+ T cell analysis were 
not significant (Fig. 4d–f). No significant correlation was observed in HD, except for the one between the IFNγ 
response and CD25+CD134+CD8+ T cells (r = 0.63, p = 0.035, r2 = 0.40) (data not shown).
In vitro assays. In another set of experiments, we determined whether the functional capacity of T cells could 
be affected by the addition of anti-TNF agents in culture. PBMCs and whole blood of 3 HD were stimulated with 
PHA in the absence or presence of increasing concentrations of TNF antagonists to examine the IFNγ response, 
the surface co-expression of CD25 and CD134, and the proliferative capacity of T cells (Table 3).
The addition of different concentrations of Eta resulted in no effects on IFNγ levels compared with 
PHA-stimulated culture as positive control (p = 0.2) (Supplementary Fig. S2). In contrast, a significant decrease 
in the IFNγ release was observed in the presence of all concentrations of Ada, with the greatest effect seen at peak 
(10 μg/mL) and supratherapeutic concentration of the drug (15 μg/mL) (p = 0.0032) (Supplementary Fig. S2).
We further examined the co-expression of CD25 and CD134 in lymphocyte subsets upon addition of increas-
ing drug concentrations after 44 hours of whole blood culture. A slight, albeit not significant, decrease of the 
co-expression of CD25 and CD134 on both T cell subsets was observed in the presence of all Eta concentrations 
(p = 0.7 for CD4+ and p = 0.3 for CD8+) (Supplementary Fig. S2).
Conversely, in the presence of Ada, the expression of surface markers was reduced to approximately half of 
the control values on both T cell subsets (p = 0.001 for CD4+ and p = 0.003 for CD8+) (Supplementary Fig. S2). 
Interestingly, the decrease was observed at both trough and at peak drug concentrations of Ada, but the great-
est effect was seen at supratherapeutic concentration (15 μg/mL), in which the frequency of CD25 and CD134 
Figure 2. Characterization of the ex vivo CD25+CD134+ T cell assay. (a) Representative dot plots from healthy 
donors (HD) showing the staining for CD25+CD134+ T cells in whole blood cultures in response to either 
control (left) or phytohemagglutinin (PHA) at 5 μg (right). The percentages of CD25+CD134+ T cells are shown 
in upper right quadrants. (b) Frequencies of CD25+CD134+ T cells in response to PHA in 15 IMID patients 
after 8 years of treatment with TNF antagonists and in 11 HD are shown. Statistical analysis was performed 
using the Mann-Whitney test to compare IMID and HD subjects and significant p-values are indicated. (c) 
Frequencies of CD25+CD134+ T cells were assessed according to the type of biological agent. Statistical analysis 
was performed using the Mann-Whitney test to compare subjects treated with Eta and Ada. Horizontal bars 
represent the median values and horizontal dashed lines indicate the cut-off of positive response corresponding 
to 0.47% (mean 0.098, SD 0.12) for CD4+ T cells, and 0.41% (mean 0.11, SD 0.09) for CD8+ T cells. The cut-off 
for a positive response was calculated as the mean response (%) ± 3SD of negative control.
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decreased from 37.2% to 18.5% among CD4+ T cells (p = 0.001) and from 12.3% to 6.1% among CD8+ T cells 
(p = 0.003). Thus, these data show that Ada decreased the in vitro response in a dose-dependent fashion.
Finally, we investigated the in vitro influence of anti-TNF agents on the proliferation of PHA-stimulated lym-
phocytes after 5 days of incubation. The cell viability, assessed by trypan blue (Sigma-Aldrich, Germany), was 
>95% for cells after 44 hours of incubations, and decreased to 75% after 5 days in all culture conditions, irrespec-
tive of the anti-TNF agent used. The addition of TNF antagonists revealed no significant changes in the prolifer-
ative response of CD4+ and CD8+ T cells with respect to PHA-stimulated controls, showing a similar trend with 
Eta and Ada (p > 0.05 for all comparisons) (Supplementary Fig. S2).
In summary, the addition of TNF antagonists in vitro, especially Ada, resulted in a decrease of IFNγ response, 
paralleled by the decrease of the co-expression of CD25 and CD134 on T cell subsets, whereas no effect on the 
intensity of the proliferative response, regardless of the drug used, was observed (p > 0.05 for all comparisons).
Discussion
This is the first long-term study examining the ex vivo and in vitro effects of TNF antagonists on T cell activa-
tion and function in IMID patients over an 8-year treatment period. We previously observed dynamic changes 
in IFNγ levels from QFT-GIT test performed in patients with rheumatic diseases during the initial 18 months 
of treatment with biological therapy22. This observation, not associated with modifications in clinical status of 
the patients, made the input to prolong the follow-up in order to investigate whether a longer treatment with 
TNF antagonists in patients with IMID might affect the function of T cells and favor the emergence of adverse 
clinical consequences. We restricted our observation to patients treated for at least 8 years. First of all, we aimed 
at evaluating the effector function of T cells at established time points (at baseline, and after 1, 2, 4, and 8 years 
of treatment with anti-TNF agents) by means of QFT-GIT. Interestingly, while no differences were observed in 
the rate of indeterminate results, the quantitative mitogen-induced IFNγ responses significantly increased with 
respect to baseline at each time point except for T4 determination, when IFNγ levels were comparable to baseline. 
However, neither clinical events were observed at any time points throughout the study nor technical reasons may 
be advocated to explain the mitogen impairment at T4. Because these results were confirmed irrespective of the 
Figure 3. Ex vivo proliferation assay of CD4+ and CD8+ T cells. (a) Representative proliferation dot plots 
of CD4+ and CD8+ T cells in healthy donors (HD). The proliferation was assessed staining PBMCs with the 
fluorescent dye Cell Trace Violet (CTV) and determining the CTV content of CD4+ and CD8+ T cells after 5 
days of stimulation with medium alone (left) or phytohemagglutinin (PHA) at 5 μg (right). In response to PHA, 
the figure depicts CD4+ and CD8+ T cells that have divided 3–4 times based on CTV dilution intensity; in 
contrast, in medium alone, the T cells did not show any divisions. (b) Cumulative analyses of the frequency of 
CD4+ and CD8+ T cells endowed with the proliferation ability in response to PHA in IMID patients (n = 15) 
and HD subjects (n = 11). Statistical analysis was performed using the Mann-Whitney test to compare IMID 
and HD subjects and significant p-values are indicated. (c) Frequencies of proliferating T cells were assessed 
according to the type of biological agent. Statistical analysis was performed using the Mann-Whitney test to 
compare subjects treated with Eta and Ada. The proliferation of T cells was expressed as the percentage of CD4+ 
and CD8+ T cells in CTVlow gate. Horizontal bars represent the median values.
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treatment (Eta or Ada) and disease (RA or PsA), it seems that TNF antagonists do not impair the effector function 
of T cells, although the source of IFNγ production (i.e. NK cells) could not be precisely defined by using a whole 
blood assay30. These data are in agreement with those reported in several studies in patients with RA or spondy-
loarthritis12,13,31–33 in which, however, the follow-up ranged from 28 days to 6 months, being indeed far shorter 
than ours. The increased IFNγ expression upon long-term anti-TNF treatment probably finds a biological basis 
on the observation that chronic TNF exposure makes Th1 cells hyporesponsive, due to an attenuated calcium 
mobilization after T cell receptor activation; consequently, blocking endogenous TNF might have the effect of 
enhancing T cell responsiveness, thus reversing the T cell anergy induced by TNF exposure31,34. Consistent with 
this hypothesis, we subsequently found an increased expression of surface activation markers on both CD4+ and 
CD8+ T cells, as well as a valuable level of proliferating T cells. In particular, the stimulation of T cells by antigen 
or mitogen resulted in the up-regulation of CD25 (interleukin-2 receptor alpha, IL-2Rα) and CD134 (a TNF 
Figure 4. Correlations between IFNγ secretion, co-expression of activation markers, and lymphocyte 
proliferation in response to phytohemagglutinin. The ex vivo immunologic assays of all IMID subjects were 
correlated using Pearson correlation coefficients. (a) IFNγ response to phytohemagglutinin (PHA) was 
positively correlated with the frequency of CD25+CD134+ CD4+ T cells (r = 0.58, p = 0.028, r2 = 0.34), (b) 
but not with the CD4+ T cells proliferating in response to PHA (r = −0.18, p = 0.5, r2 = 0.034). (c) Lack of 
correlation between frequencies of CD25+CD134+ CD4+ T cells and CD4+ T cell proliferation (r = 0.15, p = 0.5, 
r2 = 0.023). (d–f) Lack of correlation in all CD8+ T cell analysis.
In vitro effects of biological therapy
IFNγ (IU/mL)
% CD25+CD134+ T cells % proliferating T cells
CD4+ CD8+ CD4+ CD8+
No treatment 19.3 ± 2.5 58.9 ± 20.9 41.6 ± 17.6 66.1 ± 16.8 70.8 ± 10.1
Eta (1 μg/mL) 19 ± 2.9 43.2 ± 27.5 24.0 ± 16.8 71.4 ± 17.5 71.5 ± 6.3
Eta (2 μg/mL) 18.5 ± 1.6 41.0 ± 26.9 23.7 ± 17.5 71.2 ± 12.8 73 ± 6.5
Eta (5 μg/mL) 14.6 ± 5.1 48.5 ± 17.8 25.2 ± 12.8 70.2 ± 21.6 81.8 ± 14
No treatment 20 ± 0.2 37.1 ± 1.1 12.3 ± 0.5 88 ± 5.1 86.4 ± 11.4
Ada (5 μg/mL) 15 ± 2.9 21.9 ± 5.2 9 ± 1.9 86.9 ± 4.2 84.9 ± 7.7
Ada (10 μg/mL) 11.8 ± 3.3 23.2 ± 4.5 7.3 ± 1.6 85.9 ± 5.1 83.1 ± 9
Ada (15 μg/mL) 12.4 ± 2.5 18.5 ± 0.8 6.1 ± 1 86.1 ± 4.2 82.2 ± 11.5
Table 3. Results from in vitro experiments: evaluation of IFNγ response, co-expression of CD25/CD134, 
and proliferation of T cells. The results are expressed as mean ± standard deviation. Note: Eta = etanercept; 
Ada = adalimumab.
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receptor superfamily member) surface activation markers, as measured by a flow cytometry-based assay35. We 
decided to evaluate CD25 and CD134 expression since these markers were recognized to be extremely sensitive 
and specific tools for the assessment of functional response by individual T cell subsets to a variety of stimuli35. 
Indeed, interactions between CD134 and its ligand are critical for memory T cell development and effector T 
cell survival36, and the up-regulation of the high-affinity IL-2Rα via CD25 is critical for the proliferation and 
differentiation of T cells37. In the current study, we used the CD25/CD134 assay to measure a broad polyclonal 
response to PHA mitogen, providing a simple assay of T lymphocyte function. We found a relatively high propor-
tion of activated T cells in response to PHA in IMID patients, with a slightly enhanced expression of CD25 and 
CD134 markers on T lymphocytes upon Ada therapy. These findings parallel those of a recent report showing a 
significant increase in the expression of activation markers during the course of anti-TNF treatment13. In addi-
tion, among our IMID subjects, the co-expression of activation markers showed a positive correlation with IFNγ 
production. Conversely, no correlation between the co-expression of activation markers and T cell proliferation 
was found, in line with the observation of similar levels of proliferating T cells between IMID subjects and HD. 
Indeed, only a small increase in CD4+ and CD8+ T cell proliferation rate was observed following Ada treatment, 
as previously reported31, although in other studies circulating CD4+ T lymphocyte numbers remained unaffected 
in patients treated with TNF antagonists38,39, including Ada40.
While our ex vivo findings are compatible with the assumption that TNF is a negative regulator of T cell 
function13, we achieved opposite results when evaluating the in vitro impact of anti-TNF agents. In fact, the 
addition of these drugs, especially Ada, induced a significant decrease of both the IFNγ response and the 
co-expression of CD25 and CD134 on CD4+ and CD8+ T cells, whereas no effect on the intensity of the prolif-
erative response, regardless of the drug used, was observed. This finding cannot be explained by a possible toxic 
effect of Ada, since the cell death rate was less than 25% after 5 days of stimulation in all culture conditions. 
Indeed, although there was a slight decrease in vitality, no difference of cell viability between the two different 
conditions was observed. This finding was confirmed by the observation that the proliferative response of 
CD4+ and CD8+ T cells, with respect to PHA-stimulated controls, did not reveal any significant differences 
between Ada and Eta. Interestingly, conflicting effects of T cells by different anti-TNF molecules have been 
described in other studies showing that the monoclonal anti-TNF antibodies infliximab and Ada inhibited 
in vitro the T cell activation and IFNγ production, whereas the soluble TNF receptor Eta did not9,11. In this 
respect, measuring serum drug levels at the different time points could have been of help in interpreting our 
results; however, this evaluation was not performed.
The stability of immune function observed over time in our patients receiving Eta is in agreement with the 
results of a study showing no significant differences between patients treated with Eta or placebo in the sur-
face antigen phenotypes of peripheral blood leukocytes, T cell proliferative responses, neutrophil function, 
delayed-type hypersensitivity reactions, serum immunoglobulin levels, or incidence of infections41.
The different effects of Ada and Eta on the biological functions of T cells may indicate that, despite sharing a 
common therapeutic target, the anti-TNF agents may have different mechanisms of action depending on their 
molecular structure, while the differences between the ex vivo and in vitro outcome could reflect the distinct 
microenvironment supporting the biological response.
Overall, our data, though related to a small cohort of patients and the absence of a group of IMID patients 
not treated with anti-TNF treatment, do not show an impairment in the lymphocyte function over the long-term 
treatment with anti-TNF agents with respect to baseline, prior to the onset of biological agents. Furthermore, the 
small sample size did not allow evaluating the different effects on T cells of the combination therapy with gluco-
corticoids and/or conventional immunomodulators. In line with this observation, we did not observe any adverse 
effects during the course of treatment and, accordingly, recent studies at low risk of bias did not find an increased 
risk of infections in patients with RA treated with TNF antagonists42,43. Furthermore, the immune response fol-
lowing vaccination was comparable between IMID patients treated with TNF blockers and healthy controls, and 
formal guidelines for the use of vaccines in patients with IMID have been published44.
In conclusion, our study indicates that the long-term treatment with anti-TNF agents does not affect the func-
tional capacity of T cells; rather, it seems that TNF antagonists may favor the restoration of the cellular immune 
function as evidenced by the increase of IFNγ production, the presence of activated T cells and the good prolif-
erative capacity of T cells compared to HD. These results provide the biological basis for the reassuring issues on 
the safety of long-term anti-TNF treatment in patients with IMID.
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